Amphastar Pharma (AMPH) Misses Q2 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2018
August 8, 2018 4:05 PM EDTReports Net Revenues of $71.0 Million for the Three Months Ended June 30, 2018
RANCHO CUCAMONGA, Calif., Aug. 08, 2018 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (Amphastar or the Company) today reported results for the three months ended June 30, 2018.
Second Quarter Highlights
Net revenues of $71.0 million for the second quarterGAAP net loss of $2.8 million, or $0.06 per diluted share, for the second quarterAdjusted non-GAAP net income of $1.2 million, or $0.03 per diluted share, for the second quarterDr. Jack Zhang, Amphastars CEO, commented: We had an exciting three months with FDA... More
